Johns Hopkins Frailty Science #FrailtyFighter(@FrailtyScience) 's Twitter Profileg
Johns Hopkins Frailty Science #FrailtyFighter

@FrailtyScience

Follow us for news and announcements & visit https://t.co/O9fj2ea7HX for much more content on #frailty & #resiliency in #older #adults! #FrailtyFighter

ID:1189975759357501441

calendar_today31-10-2019 18:41:57

26,1K Tweets

2,3K Followers

3,1K Following

Global Frailty Network(@GlobalFrailty) 's Twitter Profile Photo

You are invited to the next webinar of the Global Frailty Network FSS Wednesday, April 10th, 2024, 12 PM ET. Dr. Emiel O. Hoogendijk from VU University Med Ctr, the Netherlands will present 'Recent Developments in Frailty Epidemiology.' Please REGISTER at mhs.webex.com/weblink/regist…

You are invited to the next webinar of the Global Frailty Network FSS Wednesday, April 10th, 2024, 12 PM ET. Dr. Emiel O. Hoogendijk from VU University Med Ctr, the Netherlands will present 'Recent Developments in Frailty Epidemiology.' Please REGISTER at mhs.webex.com/weblink/regist…
account_circle
Erin D. Michos, M.D.(@ErinMichos) 's Twitter Profile Photo

A new PCSK9i! is a novel small recombinant fusion protein of PCSK9 binding domain (adnectin) dosed SC monthly reduced LDL by ~60%, safely, with >90% of very high risk & high risk pts achieving the stringent ESC LDL targets.

A new PCSK9i! #Lerodalcibep is a novel small recombinant fusion protein of PCSK9 binding domain (adnectin) dosed SC monthly reduced LDL by ~60%, safely, with >90% of very high risk & high risk pts achieving the stringent ESC LDL targets. #ACC24 #Lipids #LBCT
account_circle
Christoph Burch(@ChristophBurch) 's Twitter Profile Photo

Sedentary lifestyle, physical activity, and gastrointestinal diseases: evidence from mendelian randomization analysis…
thelancet.com/journals/ebiom…

account_circle
NEJM(@NEJM) 's Twitter Profile Photo

Presented at :

Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx

Presented at #ACC24: Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx
account_circle
Eric Topol(@EricTopol) 's Twitter Profile Photo

This drug class is exceeding all expectations, well beyond weight loss, with new clinical trial data this week for heart disease and
A rundown and where we're headed in the new Ground Truths (link in profile) and a companion podcast w/ Daniel J Drucker

This drug class is exceeding all expectations, well beyond weight loss, with new clinical trial data this week for heart disease and #Parkinsons A rundown and where we're headed in the new Ground Truths (link in profile) and a companion podcast w/ @DanielJDrucker
account_circle
Agingdoc⭐David Barzilai🔔MD PhD MS MBA DipABLM🩺(@agingdoc1) 's Twitter Profile Photo

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

molecular-cancer.biomedcentral.com/articles/10.11…

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy molecular-cancer.biomedcentral.com/articles/10.11…
account_circle
Ian Weissman, DO(@DrIanWeissman) 's Twitter Profile Photo

Loneliness is considered a global public health issue. The U.S. surgeon general released an advisory report in 2023 documenting an epidemic of and a pressing need to increase social connection.
theconversation.com/loneliness-can…

account_circle
NEJM(@NEJM) 's Twitter Profile Photo

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC #ACC24
account_circle
JAMA(@JAMA_current) 's Twitter Profile Photo

In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types but is not suitable for others, finds meta-analysis of 41 RCTs. ja.ma/3Uf3jG9

In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types but is not suitable for others, finds meta-analysis of 41 RCTs. ja.ma/3Uf3jG9 #AACR24
account_circle
nature(@Nature) 's Twitter Profile Photo

A diabetes drug related to the latest generation of obesity drugs can slow the development of the symptoms of Parkinson’s disease go.nature.com/3U72YF2

account_circle